Blockchain Registration Transaction Record

Marijuana Compounds May Reverse Chronic Liver Disease, Study Finds

Hebrew University research finds marijuana compounds may reverse chronic liver disease affecting 1/3 of adults. Study supports cannabis companies like Canopy Growth Corp. CNW420 covers industry developments.

This research matters because it represents a significant step toward legitimizing cannabis as medicine beyond anecdotal evidence. For the one-third of adults affected by chronic liver illnesses worldwide, this could mean access to new, potentially more effective treatments. For investors and the cannabis industry, it validates long-held claims about therapeutic potential, potentially accelerating regulatory acceptance and market growth. The study's focus on reversing rather than just managing symptoms suggests cannabis compounds might address root causes of disease, which could transform treatment paradigms for various conditions beyond liver disorders.